0001144204-17-047185.txt : 20170908 0001144204-17-047185.hdr.sgml : 20170908 20170908115826 ACCESSION NUMBER: 0001144204-17-047185 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20170905 FILED AS OF DATE: 20170908 DATE AS OF CHANGE: 20170908 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hamill John P. CENTRAL INDEX KEY: 0001716213 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36598 FILM NUMBER: 171075587 MAIL ADDRESS: STREET 1: 4092 NEW HOPE ROAD CITY: FURLONG STATE: PA ZIP: 18925 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cellectar Biosciences, Inc. CENTRAL INDEX KEY: 0001279704 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043321804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3301 AGRICULTURE DRIVE CITY: MADISON STATE: WI ZIP: 53716 BUSINESS PHONE: (608) 441-8120 MAIL ADDRESS: STREET 1: 3301 AGRICULTURE DRIVE CITY: MADISON STATE: WI ZIP: 53716 FORMER COMPANY: FORMER CONFORMED NAME: NOVELOS THERAPEUTICS, INC. DATE OF NAME CHANGE: 20050617 FORMER COMPANY: FORMER CONFORMED NAME: COMMON HORIZONS INC DATE OF NAME CHANGE: 20040211 3 1 v474832_form3.xml FORM 3 X0206 3 2017-09-05 1 0001279704 Cellectar Biosciences, Inc. CLRB 0001716213 Hamill John P. C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE MADISON WI 53716 0 1 0 0 Interim CFO No securities are beneficially owned. Exhibit 24 - Power of Attorney /s/ Gregory J. Lynch, Attorney-in-fact for John P. Hamill 2017-09-08 EX-24 2 v474832_ex24.htm EXHIBIT 24

Exhibit 24

 

CONFIRMING STATEMENT

 

This Statement confirms that the undersigned has authorized and designated Gregory J. Lynch, Michael H. Altman, Joshua B. Erekson, Kelly Teelin, John Hamill and Christina Blakley, each acting singly, to execute and file on the undersigned's behalf a Form ID and all Forms 3, 4, and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. The authority of Gregory J. Lynch, Michael H. Altman, Joshua B. Erekson, Kelly Teelin, John Hamill and Christina Blakley under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4, and 5 with regard to the undersigned’s ownership of or transactions in securities of Cellectar Biosciences, Inc. unless earlier revoked in writing. The undersigned acknowledges that Gregory J. Lynch, Michael H. Altman, Joshua B. Erekson, Kelly Teelin, John Hamill and Christina Blakley are not assuming any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

 

This Statement revokes the authority of any person named in any prior confirming statement relating to the undersigned’s filing obligations with respect to securities of Cellectar Biosciences, Inc. who is not named herein, and this Statement replaces and supersedes any such prior confirming statement.

 

Dated: September 1, 2017 Signed: /s/ John P. Hamill  
   
  Print Name:  John P. Hamill